Immunotherapy efficacy and gender: discovery in precision medicine.
作者信息
Ulrich Bryan C, Guibert Nicolas
机构信息
Emory School of Medicine, Atlanta, GA, USA.
Thoracic Oncology Department, Larrey Hospital, University Hospital of Toulouse, Toulouse, France.
出版信息
Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S211-S213. doi: 10.21037/tlcr.2018.08.05.
Abstract
摘要
相似文献
1
Immunotherapy efficacy and gender: discovery in precision medicine.
Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S211-S213. doi: 10.21037/tlcr.2018.08.05.
2
Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics.
Trends Pharmacol Sci. 2017 Jan;38(1):25-40. doi: 10.1016/j.tips.2016.10.012. Epub 2016 Nov 18.
3
Noninvasive imaging in cancer immunotherapy: The way to precision medicine.
Cancer Lett. 2019 Dec 1;466:13-22. doi: 10.1016/j.canlet.2019.08.009. Epub 2019 Sep 6.
4
Precision medicine in breast cancer: reality or utopia?
J Transl Med. 2017 Jun 17;15(1):139. doi: 10.1186/s12967-017-1239-z.
5
Immunotherapy in glioblastoma: emerging options in precision medicine.
CNS Oncol. 2016 Jul;5(3):175-86. doi: 10.2217/cns-2016-0009. Epub 2016 May 26.
6
Precision Medicine: Update on Diagnosis and Therapeutic Strategies of Hepatocellular Carcinoma.
Curr Med Chem. 2018;25(17):1999-2008. doi: 10.2174/0929867325666180117101532.
7
Precision Medicine-Enabled Cancer Immunotherapy.
Cancer Treat Res. 2019;178:189-205. doi: 10.1007/978-3-030-16391-4_7.
8
Cancer Precision Medicine: From Cancer Screening to Drug Selection and Personalized Immunotherapy.
Trends Pharmacol Sci. 2017 Jan;38(1):15-24. doi: 10.1016/j.tips.2016.10.013. Epub 2016 Nov 12.
9
Sex and Gender Influences on Cancer Immunotherapy Response.
Biomedicines. 2020 Jul 21;8(7):232. doi: 10.3390/biomedicines8070232.
10
The road map of cancer precision medicine with the innovation of advanced cancer detection technology and personalized immunotherapy.
Jpn J Clin Oncol. 2019 Jul 1;49(7):596-603. doi: 10.1093/jjco/hyz073.
引用本文的文献
1
Sex differences in adverse events among cancer patients receiving immune checkpoint inhibitors: the MOUSEION-07 systematic review and meta-analysis.
Sci Rep. 2024 Nov 16;14(1):28309. doi: 10.1038/s41598-024-71746-z.
2
The Role of Estrogen and Estrogen Receptors in Head and Neck Tumors.
Cancers (Basel). 2024 Apr 19;16(8):1575. doi: 10.3390/cancers16081575.
3
Treatment patterns, clinical outcomes, and healthcare resource use associated with advanced/metastatic lung cancer in China: protocol for a retrospective observational study.
Transl Lung Cancer Res. 2020 Dec;9(6):2460-2468. doi: 10.21037/tlcr-20-1269.
4
Differences in men and women suffering from CRSwNP and AERD in quality of life.
Eur Arch Otorhinolaryngol. 2021 May;278(5):1419-1427. doi: 10.1007/s00405-020-06418-5. Epub 2020 Oct 15.
5
Sex and Gender Influences on Cancer Immunotherapy Response.
Biomedicines. 2020 Jul 21;8(7):232. doi: 10.3390/biomedicines8070232.
6
Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic Parameters.
Cancers (Basel). 2020 May 27;12(6):1373. doi: 10.3390/cancers12061373.
7
Impact of clinicopathological features on the efficacy of immune checkpoint inhibitors plus conventional treatment in patients with advanced lung cancer.
J Thorac Dis. 2019 Sep;11(9):3794-3807. doi: 10.21037/jtd.2019.09.19.
8
Non-invasive assessment of tumor PD-L1 status with circulating tumor cells.
Ann Transl Med. 2018 Nov;6(Suppl 1):S48. doi: 10.21037/atm.2018.10.09.
本文引用的文献
1
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.
Lancet Oncol. 2018 Jun;19(6):737-746. doi: 10.1016/S1470-2045(18)30261-4. Epub 2018 May 16.
2
Tumor Mutational Burden and Response Rate to PD-1 Inhibition.
N Engl J Med. 2017 Dec 21;377(25):2500-2501. doi: 10.1056/NEJMc1713444.
3
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.
J Thorac Oncol. 2017 Feb;12(2):208-222. doi: 10.1016/j.jtho.2016.11.2228. Epub 2016 Nov 29.
4
Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma.
J Thorac Oncol. 2016 Nov;11(11):1879-1890. doi: 10.1016/j.jtho.2016.06.006. Epub 2016 Jun 23.
5
Analysis of ultra-deep targeted sequencing reveals mutation burden is associated with gender and clinical outcome in lung adenocarcinoma.
Oncotarget. 2016 Apr 19;7(16):22857-64. doi: 10.18632/oncotarget.8213.
6
Gender Disparity and Mutation Burden in Metastatic Melanoma.
J Natl Cancer Inst. 2015 Aug 20;107(11). doi: 10.1093/jnci/djv221. Print 2015 Nov.
7
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Science. 2015 Apr 3;348(6230):124-8. doi: 10.1126/science.aaa1348. Epub 2015 Mar 12.
8
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.
Mol Cancer Ther. 2015 Apr;14(4):847-56. doi: 10.1158/1535-7163.MCT-14-0983. Epub 2015 Feb 18.
9
Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities.
Crit Rev Oncol Hematol. 2014 Jan;89(1):140-65. doi: 10.1016/j.critrevonc.2013.08.002. Epub 2013 Aug 28.
10
Tumor immunotherapy directed at PD-1.
N Engl J Med. 2012 Jun 28;366(26):2517-9. doi: 10.1056/NEJMe1205943. Epub 2012 Jun 2.
Zotero 插件